Press releases

Full focus on the phase III study CONCLUDE with cobitolimod

May 12, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will be exhibiting at the Digestive Disease Week (DDW) May 21-24, 2022 in San Diego. DDW is the world’s premier meeting for healthcare professionals, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

May 2, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Eva Arlander as Chief Development Officer. Eva will also be part of the management team, together with acting Chief Executive Officer and Chief Financial Officer Johan Giléus, Chief Medical Officer Anders Bröijersén and Chief Scientific Officer Charlotte Admyre.

28 April 2022 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Wednesday 1 June, 2022 at 17.00 (CET) through advance voting. Attendance at the meeting is only possible via postal ballot.

April 11, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that after more than seven years as CEO, Peter Zerhouni has decided to leave his position. The company’s CFO Johan Giléus has been appointed acting CEO while a new CEO is being recruited, and he will also continue as CFO.

April 8, 2022 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2021. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.

March 13, 2022 – InDex Pharmaceuticals Holding AB (publ) is planning for self-commercialisation of the drug candidate cobitolimod in the US with strategic collaborations in other regions. Launch is expected in 2027, with the potential for annual sales to reach more than USD 1 billion, in moderate to severe left-sided ulcerative colitis. An in-depth presentation of the strategy and market potential, together with the execution of the phase III study CONCLUDE with cobitolimod will be provided at InDex’s Capital Markets Day, tomorrow March 14, 15.00-17.00 CET.

March 7, 2022 – InDex Pharmaceuticals Holding AB (publ) invites investors, analysts and media to a Capital Markets Day on March 14, 2022. The Capital Markets Day will be held in Krügersalen at Kapitel 8, Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm. The presentations will start at 15.00 CET with registration from 14.30 CET.

First patient enrolled in the phase III study CONCLUDE

February 15, 2022 – InDex Pharmaceuticals Holding AB (publ) invites investors, analysts and media to a Capital Markets Day on March 14, 2022. The Capital Markets Day will be held in Krügersalen at Kapitel 8, Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm. The presentations will start at 15.00 CET with registration from 14.30 CET.

February 13, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that Chief Operating Officer Pernilla Sandwall has decided to leave the company to become CEO of WntResearch. She will continue in her current role until the end of April. The process to recruit her successor will be initiated immediately.